

IN THE CLAIMS

1. (original) An isolated polynucleotide encoding a polypeptide that comprises the amino acid sequence shown in SEQ ID NO:2.
2. (currently amended) The isolated polynucleotide of claim 1 which comprises ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1.
3. (currently amended) The isolated polynucleotide of claim 1 which consists of ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1.
4. (original) The isolated polynucleotide of claim 1 which is a cDNA molecule.
- 5 (original) An expression vector comprising a polynucleotide that encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
6. (currently amended) The expression vector of claim 5 which comprises ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1.
7. (original) A host cell comprising an expression vector comprising a polynucleotide that encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
8. (currently amended) The host cell of claim 7 wherein the expression vector comprises ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1.
9. (withdrawn) A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
10. (withdrawn) The purified polypeptide of claim 9 which consists of the amino acid sequence of SEQ ID NO:2.
11. (withdrawn) A fusion protein comprising a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:2.

12. (currently amended) A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of: culturing a host cell comprising an expression vector that comprises ~~comprising the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1 under conditions whereby the polypeptide is expressed; and isolating the polypeptide.

13. (withdrawn) A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of: hybridizing to nucleic acid material of a biological sample a polynucleotide comprising 11 contiguous nucleotides of the complement of ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1, thereby forming a hybridization complex; and detecting the hybridization complex.

14. (withdrawn) The method of claim 13 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.

15. (withdrawn) A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising: a polynucleotide comprising 11 contiguous nucleotides of the complement of ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1; and instructions for the method of claim 13.

16. (withdrawn) A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of: contacting a biological sample with an antibody that specifically binds to the polypeptide to form a reagent-polypeptide complex; and detecting the reagent-polypeptide complex.

17. (withdrawn) A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising: an antibody that specifically binds to the polypeptide; and instructions for the method of claim 16.

18. (withdrawn) A method of screening for agents that can regulate the activity of an neuropeptide Y-like G protein-coupled receptor (NPY-like GPCR), comprising the steps of: contacting a test compound with a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and detecting binding of the test compound to the polypeptide, wherein a test compound that binds to the polypeptide is identified as a potential agent for regulating activity of the NPY-like GPCR.

19. (withdrawn) The method of claim 20 wherein the step of contacting is in a cell.

20. (withdrawn) The method of claim 20 wherein the step of contacting is in vitro.

21. (withdrawn) The method of claim 20 wherein the step of contacting is in a cell-free system.

22. (withdrawn) The method of claim 20 wherein the first polypeptide comprises a detectable label.

23. (withdrawn) The method of claim 20 wherein the test compound comprises a detectable label.

24. (withdrawn) The method of claim 20 wherein the test compound displaces a ligand that is bound to the NPY-like GPCR.

25. (withdrawn) The method of claim 20 wherein the first polypeptide is bound to a solid support.

26. (withdrawn) The method of claim 20 wherein the test compound is bound to a solid support.

27. (withdrawn) A method of screening for agents that can regulate the activity of an NPY-like GPCR, comprising the steps of: contacting a test compound with a product encoded by a polynucleotide comprising ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1; and detecting binding of the test compound to the product, wherein a test compound that binds to the product is identified as a potential agent for regulating the activity of the NPY-like GPCR.

28. (withdrawn) The method of claim 27 wherein the product is a polypeptide.

29. (withdrawn) The method of claim 27 wherein the product is RNA.

30. (withdrawn) A method of reducing expression of an NPY-like GPCR, comprising the step of: contacting a cell with an antibody that specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, whereby expression of the NPY-like GPCR is reduced.

31. (withdrawn) The method of claim 30 wherein the cell is in vivo.

32. (withdrawn) The method of claim 30 wherein the cell is in vitro.

33. (withdrawn) A method of reducing expression of an NPY-like GPCR, comprising the step of: contacting a cell with an antisense oligonucleotide that specifically binds to ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1, whereby expression of the NPY-like GPCR is reduced.

34. (withdrawn) The method of claim 33 wherein the cell is in vivo.

35. (withdrawn) The method of claim 33 wherein the cell is in vitro.

36. (withdrawn) A pharmaceutical composition, comprising: an antibody that specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and a pharmaceutically acceptable carrier.

37. (withdrawn) A pharmaceutical composition, comprising: an antisense oligonucleotide that specifically binds to ~~the open reading frame contained within~~ the nucleotide sequence shown in SEQ ID NO:1; and a pharmaceutically acceptable carrier.

38. (canceled)

39. (canceled)